Elucidating the mechanism of Kuwanon G in treating diabetic encephalopathy through network pharmacology: A comprehensive study

doi:10.5246/jcps.2025.03.019

Abstract

Abstract:

The present study employed network pharmacology to elucidate the molecular mechanism underlying the therapeutic effects of kuwanon G in diabetic encephalopathy. Utilizing the Pharmmapper databases, we identified potential targets associated with kuwanon G. Simultaneously, targets related to diabetic encephalopathy were screened. The VENNY software facilitated the identification of 34 common target genes, forming the basis for constructing a protein-protein interaction network map via the STRING database. GO enrichment and KEGG pathway analyses were conducted using the David database, with Cytoscape software employed to pinpoint key target genes. Results revealed 101 potential targets for kuwanon G and 1058 for diabetic encephalopathy, with an overlap of 34 target genes. Notably, GSK3B, CASP3, MAKP14, ESR1, and PPARG emerged as pivotal genes in the therapeutic action of kuwanon G against diabetic encephalopathy. Pathway analysis of these key genes indicated that kuwanon G exerted its therapeutic effects through modulating pathways associated with lipid and atherosclerosis, fluid shear stress and atherosclerosis, IL-17 signaling, and the AGE-RAGE signaling pathway. This study offered valuable insights into the potential molecular mechanisms of kuwanon G in treating diabetic encephalopathy, presenting a novel framework for future research in this domain.

Key words: Kuwanon G, Network pharmacology, Diabetic encephalopathy, Mechanism

Supporting:

Yuqian Zhang, Haiying Niu, Xiaowei Zhang, Weiwei Xie, Kaiyue Zhang, Lantong Zhang, Yiran Jin. Elucidating the mechanism of Kuwanon G in treating diabetic encephalopathy through network pharmacology: A comprehensive study[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(3): 251-259.

Figures/Tables 5

References 28

[1]	International Diabetes Federation. IDF Diabetes Atlas-7th Edition [EB/OL]. http://www.diabetesatlas.org, 2021-06-08.
[2]	Markowicz-Piasecka, M.; Sikora, J.; Szydłowska, A.; Skupień, A.; Mikiciuk-Olasik, E.; Huttunen, K.M. Metformin-A future therapy for neurodegenerative diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer’s Disease Guest Editor: Davide Brambilla. Pharm. Res. 2017, 34, 2614–2627.
[3]	Bogush, M.; Heldt, N.A.; Persidsky, Y. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J. Neuroimmune Pharmacol. 2017, 12, 593–601.
[4]	Abou-El-Hassan, H.; Dia, B.; Choucair, K.; Eid, S.A.; Najdi, F.; Baki, L.; Talih, F.; Eid, A.A.; Kobeissy, F. Traumatic brain injury, diabetic neuropathy and altered-psychiatric health: The fateful triangle. Med. Hypotheses. 2017, 108, 69–80.
[5]	Belanger, A.; Lavoie, N.; Trudeau, F.; Massicotte, G.; Gagnon, S. Preserved LTP and water maze learning in hyperglycaemic–hyperinsulinemic ZDF rats. Physiol. Behav. 2004, 83, 483–494.
[6]	Zeng, W.Y.; Suo, Y.R.; Li, H.H.; Wei, B.; Sun, Y.X.; Yang, L.; Jiang, X.J. Research progress of active components of traditional Chinese medicine on prevention of diabetic cognitive deficits. Liaoning J. Tradit. Chin. Med. 2017, 44, 2667–2671.
[7]	Zhou, L.P.; Zhamg, X.K.; Wang, F. Experimental Research Progress on Prevention and Treatment of Cognitive Dysfunction in Diabetes Mellitusby Traditional Chinese Medicine. Chin. J. Exp. Tradit. Med. Form. 2019, 25, 227–234.
[8]	Jung, H.W.; Kang, S.Y.; Kang, J.S.; Kim, A.R.; Woo, E.R.; Park, Y.K. Effect of Kuwanon G isolated from the root bark of Morus alba on ovalbumin-induced allergic response in a mouse model of asthma. Phytother. Res. 2014, 28, 1713–1719.
[9]	Liu, X.X.; Zhang, X.W.; Wang, K.; Wang, X.Y.; Ma, W.L.; Cao, W.; Mo, D.; Sun, Y.; Li, X.Q. Kuwanon G attenuates atherosclerosis by upregulation of LXRα-ABCA1/ABCG1 and inhibition of NFκB activity in macrophages. Toxicol. Appl. Pharmacol. 2018, 341, 56–63.
[10]	Gan, W.J.; Gao, C.L.; Zhang, W.Q.; Gu, J.L.; Zhao, T.T.; Guo, H.L.; Zhou, H.; Xu, Y.; Yu, L.L.; Li, L.F.; Gui, D.K.; Xu, Y.H. Kuwanon G protects HT22 cells from advanced glycation end product-induced damage. Exp. Ther. Med. 2021, 21, 425.
[11]	Yang, T.; Chen, X.; Mei, Z.; Liu, X.; Feng, Z.; Liao, J.; Deng, Y.; Ge, J. An integrated analysis of network pharmacology and experimental validation to reveal the mechanism of Chinese medicine formula Naotaifang in treating cerebral ischemia-reperfusion injury. Drug Des. Devel. Ther. 2021, 15, 3783–3808.
[12]	Dong, Y.; Hao, L.; Fang, K.; Han, X.X.; Yu, H.; Zhang, J.J.; Cai, L.J.; Fan, T.; Zhang, W.D.; Pang, K.; Ma, W.M.; Wang, X.T.; Han, C.H. A network pharmacology perspective for deciphering potential mechanisms of action of Solanum nigrum L. in bladder cancer. BMC Complement. Med. Ther. 2021, 21, 45.
[13]	Llorens-MarÃtin, M.; Jurado, J.; HernÃ¡ndez, F.; Ãvila, J. GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 2014, 7, 46.
[14]	Engel, T.; Lucas, J.J.; Gómez-Ramos, P.; Moran, M.A.; Ávila, J.; Hernández, F. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging. 2006, 27, 1258–1268.
[15]	Su, J.H.; Zhao, M.; Anderson, A.J.; Srinivasan, A.; Cotman, C.W. Activated caspase-3 expression in Alzheimer’s and aged control brain: correlation with Alzheimer pathology. Brain Res. 2001, 898, 350–357.
[16]	Płóciennik, A.; Prendecki, M.; Zuba, E.; Siudzinski, M.; Dorszewska, J. Activated caspase-3 and neurodegeneration and synaptic plasticity in Alzheimer’s disease. Adv. Alzheimers. Dis. 2015, 4, 63–77.
[17]	Maphis, N.; Jiang, S.Y.; Xu, G.X.; Kokiko-Cochran, O.N.; Roy, S.M.; Van Eldik, L.J.; Watterson, D.M.; Lamb, B.T.; Bhaskar, K. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers. Res. Ther. 2016, 8, 54.
[18]	Schnöder, L.; Gasparoni, G.; Nordström, K.; Schottek, A.; Tomic, I.; Christmann, A.; Schäfer, K.H.; Menger, M.D.; Walter, J.; Fassbender, K.; Liu, Y. Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer’s mouse models. FASEB J. 2020, 34, 9628–9649.
[19]	Zhou, Y.L.; Du, Y.F.; Du, H.; Shao, P. Insulin resistance in Alzheimer’s disease (AD) mouse intestinal macrophages is mediated by activation of JNK. Eur. Rev. Med. Pharmaco. 2017, 21, 1787–1794.
[20]	Christiansen, A.R.; Lipshultz, L.I.; Hotaling, J.M. Selective androgenreceptor modulators: the future of androgen therapy? Transl. Androl. Urol. 2020, 9, 135–148.
[21]	Khan, M.A.; Alam, Q.; Haque, A.; Ashafaq, M.; Khan, M.J.; Ashraf, G.M.; Ahmad, M. Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer’s disease: an update. Curr. Neuropharmacol. 2019, 17, 232–246.
[22]	Mohseni-Moghaddam, P.; Ghobadian, R.; Khaleghzadeh-Ahangar, H. Dementia in diabetes mellitus and atherosclerosis: Two interrelated systemic diseases. Brain Res. Bull. 2022, 181, 87–96.
[23]	Shen, C.Y.; Lu, C.H.; Wu, C.H.; Li, K.J.; Kuo, Y.M.; Hsieh, S.C.; Yu, C.L. The development of Maillard reaction, and advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases. Molecules. 2020, 25, 5591.
[24]	Byun, K.; Yoo, Y.; Son, M.; Lee, J.; Jeong, G.B.; Park, Y.M.; Salekdeh, G.H.; Lee, B. Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol. Ther. 2017, 177, 44–55.
[25]	de Retana, S.F.; Marazuela, P.; Solé, M.; Colell, G.; Bonaterra, A.; Sánchez-Quesada, J.L.; Montaner, J.; Maspoch, D.; Cano-Sarabia, M.; Hernández-Guillamon, M. Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimers Res. Ther. 2019, 11, 42.
[26]	Yang, H.M.; Xie, T.T.; Li, D.R.; Du, X.H.; Wang, T.X.; Li, C.Y.; Song, X.J.; Xu, L.Q.; Yi, F.; Liang, X.H.; Gao, L.F.; Yang, X.D.; Ma, C.H. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-κB/TNF-α pathway. Mol. Metab. 2019, 23, 24–36.
[27]	Gabbouj, S.; Ryhänen, S.; Marttinen, M.; Wittrahm, R.; Takalo, M.; Kemppainen, S.; Martiskainen, H.; Tanila, H.; Haapasalo, A.; Hiltunen, M.; Natunen, T. Altered insulin signaling in Alzheimer’s disease brain–special emphasis on PI3K-Akt pathway. Front. Neurosci. 2019, 13, 629.
[28]	Su, F.; Shu, H.; Ye, Q.; Wang, Z.; Xie, C.; Yuan, B.; Zhang, Z.; Bai, F. Brain insulin resistance deteriorates cognition by altering the topological features of brain networks. Neuroimage Clin. 2017, 13, 280–287.